

UNITED STATES PATENT APPLICATION

**CLASSIFYING TACHYARRHYTHMIA USING TIME INTERVAL
BETWEEN VENTRICULAR DEPOLARIZATION AND MITRAL
VALVE CLOSURE**

INVENTORS

William C. Lincoln
of Coon Rapids, MN, USA

Gerrard M. Carlson
of Champlin, MN, USA

Attorney: Suneel Arora
Reg. No. 42,267
Schwegman, Lundberg, Woessner, & Kluth, P.A.
1600 TCF Tower
121 South Eighth Street
Minneapolis, Minnesota 55402
ATTORNEY DOCKET NO. 00279.647US1

CLASSIFYING TACHYARRHYTHMIA USING TIME INTERVAL BETWEEN VENTRICULAR DEPOLARIZATION AND MITRAL VALVE CLOSURE

5

TECHNICAL FIELD

The present system relates generally to cardiac rhythm management systems and particularly, but not by way of limitation, to classifying a tachyarrhythmia using a time interval between a ventricular depolarization and a mitral valve closure.

10

BACKGROUND

A cardiac rhythm management system may include an implantable cardiac rhythm management device. Such devices may provide therapy, such as to treat bradyarrhythmias and/or tachyarrhythmias. In addition to adjusting heart rate, such a device may also improve cardiac output by providing cardiac resynchronization therapy (CRT). Such CRT assists in spatially coordinating heart contractions. Different arrhythmias and/or pathological conditions may require different therapies. For example, a supraventricular tachyarrhythmia (SVT) may be treated differently from a ventricular tachyarrhythmia (VT). Therefore, it may be desirable for the system to distinguish SVT from VT.

20

One factor useful for identifying VT (such as for discriminating between SVT and VT, or otherwise) is detecting atrioventricular (AV) dissociation, in which the ventricular heart rhythm doesn't track the atrial heart rhythm. The existence of AV dissociation during a tachyarrhythmia is often an indicator of the existence of VT rather than SVT, particularly where the VT or SVT occurs during a regular heart rhythm.

25

SUMMARY

The present inventors have recognized that certain techniques of detecting AV dissociation require detecting atrial depolarizations (often referred to as a "P-wave") on an electrocardiographic (ECG) or similar heart signal. However, the

30

present inventors have recognized that some patients manifest wide ventricular depolarizations (often referred to as QRS complexes) on the ECG signal. Such wide QRS complexes may mask the P-wave. This may confound detection of AV dissociation techniques that use P-wave detection, which may, in turn, confound discrimination between VT and SVT. Accordingly, the present inventors have

5 recognized a need for obtaining additional information useful for detecting AV dissociation and/or discriminating between VT and SVT using the AV dissociation, where appropriate. The present inventors have further recognized that such additional information could be useful not only where P-wave information is difficult to obtain, but also where P-wave information is more readily obtainable.

10 Accordingly, the present document discloses cardiac rhythm management systems, devices, and methods that measure a time interval between a first fiducial marker correlative to a ventricular depolarization (e.g., a QRS complex, a Q-wave, an R-wave, etc.) and a second fiducial marker correlative to a subsequent mitral valve closure (MVC) occurring during the same cardiac cycle. Such time intervals

15 are used for detecting AV dissociation. The AV dissociation may, in turn, be used—particularly during a regular heart rhythm—for discriminating between a supraventricular tachyarrhythmia (SVT) and a ventricular tachyarrhythmia (VT) or for any other diagnostic and/or therapeutic purpose. AV dissociation occurring during a VT is referred to as AV dissociated VT, or simply dissociated VT. The AV

20 dissociation and/or SVT/VT discrimination information may be communicated from an implantable cardiac rhythm management device to an external interface and/or used to determine the nature of therapy delivered to the subject. Other aspects of the present cardiac rhythm management systems, devices, and methods will become apparent upon reading the following detailed description and viewing the drawings

25 that form a portion thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, which are not necessarily drawn to scale, like numerals

describe substantially similar components throughout the several views. Like numerals having different letter suffixes represent different instances of substantially similar components. The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document.

Figure 1 is a schematic/block diagram illustrating generally, among other things, one example of portions of a cardiac rhythm management system and an environment in which it is used.

Figure 2 is a schematic/block diagram illustrating generally one example of portions of a signal processing circuit for detecting mitral valve closures (MVCs).

Figure 3 is a schematic/block diagram illustrating generally another example of portions of a signal processing circuit for detecting MVCs, such as by using a matching filter comparing a morphology to a template.

Figure 4 is a flow chart illustrating generally one example technique for determining whether a dissociation condition exists.

Figure 5 is a flow chart illustrating generally another example technique for determining whether a dissociation condition, such as dissociated ventricular tachyarrhythmia (VT) exists.

Figure 6 is a flow chart illustrating generally, by way of example, but not by way of limitation, a further technique for determining whether dissociated VT exists.

DETAILED DESCRIPTION

In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments, which are also referred to herein as “examples,” are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that the embodiments may be combined, or that other embodiments may be utilized and that structural, logical and electrical changes may be made without departing from the scope of the present invention. The following detailed

description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims and their equivalents. In the drawings, like numerals describe substantially similar components throughout the several views. Like numerals having different letter suffixes represent different instances of substantially similar components.

5 The present systems, devices, and methods will be described in applications involving implantable medical devices including, but not limited to, implantable cardiac rhythm management devices such as pacemakers, cardioverter/defibrillators, pacer/defibrillators, biventricular or other multi-site coordination and/or cardiac resynchronization devices, and drug delivery systems. However, it is understood
10 that the present methods and apparatus may be employed in unimplanted devices, including, but not limited to, external pacemakers, cardioverter/defibrillators, pacer/defibrillators, biventricular or other multi-site coordination and/or cardiac resynchronization devices, monitors, programmers and recorders, whether such devices are used for providing a diagnostic, a therapy, or both a diagnostic and a
15 therapy.

 Figure 1 is a schematic diagram illustrating generally one example of portions of the present cardiac rhythm management system **100** and an environment in which it is used. In this embodiment, system **100** includes, among other things, an implantable or other cardiac rhythm management device **102**. The device **102** is
20 coupled to at least one electrode **104** associated with the heart **106**, such as via an intravascular lead **108**, or via at least one electrode **104C** located on a housing of the implantable device **102**.

 In one example, the electrode is “associated” with the particular heart chamber by inserting it into that heart chamber, or by inserting it into a portion of
25 the heart’s vasculature that is close to that heart chamber, or by epicardially placing the electrode outside that heart chamber, or by any other technique of configuring and situating an electrode for sensing signals and/or providing therapy with respect to that heart chamber. Device **102** may also include other electrodes, such as a

housing electrode and/or a header electrode, or even one or more external electrodes, such as may be affixed to the subject's skin.

In the example of Figure 1, device 102 includes a heart signal sensing circuit 110 having at least one input 112 coupled to electrode(s) 104 associated with the heart 106. The heart signal sensing circuit 110 typically includes an amplifier 114 to
5 receive an intrinsic ventricular heart signal. An output of the amplifier 114 is coupled to an input of a depolarization detector circuit 116, such as a level detector and/or peak detector circuit, to detect a ventricular depolarization. The ventricular depolarization is typically referred to as a QRS complex. The QRS complex is comprised of a sequence of deviations from baseline referred to as a Q-wave, an R-
10 wave, and an S-wave. The QRS complex and its constituent deviations are examples of indications of a ventricular depolarization. Upon detecting such a QRS complex, the depolarization detector circuit 116 captures a system clock time value corresponding to the occurrence of the detected QRS complex. An output 118 of the heart signal sensing circuit 110 provides information about the times
15 corresponding to the detected ventricular depolarization indications. The output 118 of the heart signal sensing circuit 110 is coupled to a first input 120 of a timer circuit 122.

In the example of Figure 1, device 102 also includes a mitral valve closure sensing circuit 123. The mitral valve closure sensing circuit 123 typically includes a
20 sensor 124, such as an accelerometer (for sensing acceleration or vibrations) and/or a microphone (for sensing acoustic energy). The mitral valve closure sensing circuit 123 also typically includes a signal processing circuit 126, which is coupled to the sensor 124. The signal processing circuit 126 outputs information about the times indicative of mitral valve closures and/or heart sounds (such as the S1 heart sound)
25 that include information indicative of a mitral valve closure. The signal processing circuit 126 outputs these times indicative of mitral valve closures to a second input 128 of the timer circuit 122.

In the example of Figure 1, the timer circuit 122 measures time intervals.

Each time interval is measured between the time indicative of the ventricular depolarization and the time indicative of a subsequent MVC occurring during the same cardiac cycle. The timer circuit **122** includes an output **130** that is coupled to an input **132** of a memory circuit **134**. The memory circuit **134** stores the time intervals. The memory circuit **134** includes an output **136** that provides the stored
5 time intervals to at least one input **138** of a processor circuit **140**. The processor circuit **140** includes executable instructions **142** for computing a QRS-to-MVC variability indicator **144** (e.g., a range, a variance, a standard deviation, etc.) of the time intervals.

In one example, the variability indicator **144** is provided to a comparator **146**
10 and compared against a predetermined threshold value. If the variability indicator **144** exceeds the threshold value, then a binary or other dissociation indicator **148** is set to “true,” or to otherwise indicate that a dissociation condition exists. In a further example, the output **118** of the heart signal sensing circuit **110** is also coupled to an input **150** of a tachyarrhythmia detector circuit **152**. In one example,
15 the tachyarrhythmia detector circuit **152** deems a tachyarrhythmia to exist when a rate between ventricular depolarizations exceeds a predetermined threshold value. An output **154** of the tachyarrhythmia detector circuit **152** is coupled to an input **156** of the processor circuit **140**. In this example, the processor circuit **140** deems a ventricular tachyarrhythmia (VT) dissociation condition to exist when both a
20 tachyarrhythmia is present and the dissociation indicator **148** is true.

In a further example, the device **102** may include a communication circuit **158** that wirelessly or otherwise communicates information indicative of whether a dissociation condition or a VT dissociation exists to an external programmer or other remote interface **160**, such as for display to a physician or other caregiver. In
25 another example, the dissociation indicator **148** is used by a therapy algorithm **162** that controls timing of delivery of anti-tachyarrhythmia or other cardiac rhythm management therapy provided by therapy control circuit **164** to the heart **106** based at least in part on whether the VT dissociation exists. In yet another example, the

described indicator of whether VT dissociation exists is used in combination with one or more other similar indicators obtained using different techniques, such as to increase the accuracy of the VT dissociation and/or SVT/VT discrimination determination.

Thus, the example device **102** illustrated in Figure **1** is capable of
5 determining whether a dissociated VT exists using only detected ventricular depolarizations and detected MVCs. This avoids any need to detect a P-wave associated with an atrial depolarization. This is particularly useful where no atrial electrode is available, or where the P-wave is obscured by a wide QRS complex, thereby making the P-wave difficult to detect. This also avoids any need to use
10 echocardiographic techniques that are typically not well suited to an implantable device **102**.

Figure **2** is a schematic diagram illustrating generally, by way of example, but not by way of limitation, one example of portions of the signal processor circuit **126** used for detecting MVCs. In the example of Figure **2**, the signal processor
15 circuit **126** includes a sensor interface circuit **200**, an analog-to-digital (A/D) converter circuit **202**, a highpass filter circuit **204**, a lowpass filter circuit **206**, a differentiator circuit **208**, and a peak or level detector circuit **210**. An input of the sensor interface circuit **200** is coupled to the sensor **124**, such as to receive an acceleration or sound signal that includes information about MVCs. The sensor
20 interface circuit **200** typically includes an amplifier circuit and any analog filtering circuits, such as an anti-aliasing filter circuit. An output of the sensor interface circuit **200** is coupled to an input of the A/D converter **202** to provide it with a sensor signal that is suitable for digitizing into an 8-bit, 10-bit, or other suitable digital sensor signal. At least one output of the A/D converter **202** is coupled to at
25 least one input of the highpass filter circuit **204** to provide it with a digital sensor signal suitable for further digital signal processing. The highpass filter circuit **204** removes or attenuates a baseline component of the digital sensor signal, such as by using a highpass filter having an effective cutoff frequency of about 1 Hz. At least

one output of the highpass filter circuit **204** is coupled to at least one input of the lowpass filter **206**. The lowpass filter **206** removes a high frequency component of its input signal, such as by using 5-sample moving average “boxcar” filter attenuating signal frequencies above approximately 100 Hz. At least one output of the lowpass filter **206** is coupled to at least one input of the differentiator **208**. At least one output of the differentiator circuit **208** is coupled to at least one input of the peak or level detector **210** to provide it with a signal having a first peak occurring between the ventricular heart contraction and a subsequent atrial heart contraction. This first peak is indicative of a MVC. The peak or level detector circuit **210** detects such peaks that are indicative of MVC using either peak or level detecting techniques, or both. Upon detecting such an MVC, the peak or level detector circuit **210** captures a system clock time value corresponding to the occurrence of the detected MVC. At least one output of the peak or level detector circuit **210** provides times associated with the MVCs to the timer circuit **122** for measuring the QRS-to-MVC time intervals, as discussed above. Other aspects of one suitable example of the signal processor circuit **126** is described in commonly assigned Lincoln et al. U.S. Patent Application Serial No. 09/862,763, filed on May 21, 2001, entitled CARDIAC RHYTHM MANAGEMENT SYSTEM DETECTING AV-DELAY BASED ON INTERVAL BETWEEN ATRIAL DEPOLARIZATION AND MITRAL VALVE CLOSURE, which is incorporated herein by reference in its entirety, including its description of an MVC fiducial point generator and associated signal processing circuitry for obtaining MVC information.

Figure 3 is a schematic diagram illustrating generally, by way of example, but not by way of limitation, an alternative example of the signal processor circuit **126**. In this example, a morphology template comparator **300** or other signal matching type filter is substituted for the peak or level detector circuit **210**. The morphology template comparator **300** includes a stored template of a portion of an input signal that is indicative of a MVC. The morphology template comparator **300** compares the shape of a portion of its input signal to the stored template indicative

of a MVC, such as by using auto-regression or similar techniques. When a close enough match is obtained, a MVC is declared. One example of matching a portion of a signal to a template is described in commonly assigned Carlson U.S. Patent No. 5,674,256 entitled CARDIAC PRE-EJECTION PERIOD DETECTION, which is incorporated herein by reference in its entirety, including its description of

5 autoregression and template matching to detect a signal feature, such as the present indications of MVCs.

Figure 4 is a flow chart illustrating generally, by way of example, but not by way of limitation, one example of a method of determining whether a dissociated VT exists. At 400, a signal is acquired to obtain first times that are indicative of

10 ventricular depolarizations. In one example, this includes acquiring an electrical intrinsic ventricular heart signal from at least one intravascular, housing, surface, or other electrode 104 associated with the heart 106. In another example, such as when the ventricular depolarization results from issuance of a pacing stimulus, the first time is instead measured from the time of issuance of the pacing stimulus or,

15 alternatively, measured from the time at which an evoked response QRS complex is detected. At 402, another signal is acquired to obtain second times that are indicative of MVCs, such as by using one or more of the various techniques described above. In one example, this MVC information is obtained from an acceleration or vibration signal provided by an accelerometer located within the

20 implantable device 102 or elsewhere. In another example, this MVC information is obtained from an acoustic signal provided by a microphone located within the implantable device 102, such as on an intravascular lead, or elsewhere. At 404, QRS-to-MVC time intervals are measured between the first times and the second times, such as by using the timer circuit 122. At 406, these time intervals are used

25 to determine whether a dissociated VT exists, such as by comparing a variability (e.g., range, variance, standard deviation, etc.) of the time intervals to a predetermined threshold value and, if such variability exceeds the threshold value, then declaring a dissociation condition to exist. In one illustrative example, the

QRS-to-MVC time intervals for the most recent 20 heart beats are collected, and a variability is calculated. In this illustrative example, if the variability exceeds a predetermined threshold value, then a dissociation condition is declared.

Figure 5 is a flow chart illustrating generally, by way of example, but not by way of limitation, a further technique for determining whether dissociated VT exists.

- 5 In the example of Figure 5, as first times indicative of ventricular depolarizations are being obtained on a beat-by-beat basis at 400, a determination of whether a tachyarrhythmia is present is made at 500. In one example, the rate between successive ventricular depolarizations is compared to a tachyarrhythmia rate threshold (e.g., 100 beats per minute) and, if this ventricular rate exceeds the
- 10 tachyarrhythmia rate threshold, then a tachyarrhythmia is declared present. In this example, only if a tachyarrhythmia is declared present at 500 are the subsequent acts 402, 404, and 406 carried out.

Figure 6 is a flow chart illustrating generally, by way of example, but not by way of limitation, a further technique for determining whether dissociated VT exists.

- 15 This technique is similar to Figure 5 in some respects, however, both second times indicative of MVCs and corresponding signal amplitudes are acquired at 602 (such as where peak or level detector 210 is implemented as a peak detector). At 604, QRS-to-MVC intervals between the first and second times are measured, and amplitudes of the processed digital sensor signal are also measured. At 606, the
- 20 QRS-to-MVC intervals and amplitudes are stored in memory. At 608, variability in the intervals and/or the amplitudes is used to determine whether a dissociated VT exists. In one example, this includes comparing a percent range (or other statistical variability indicator) of the intervals to a corresponding first predetermined threshold, as discussed above. A percent range (or other statistical variability
- 25 indicator) of the amplitudes is similarly compared to a corresponding second predetermined threshold. Only if both such variabilities exceed their thresholds is a ventricular dissociation condition deemed to exist.

It is to be understood that the above description is intended to be illustrative,

and not restrictive. For example, the above-described embodiments may be used in combination with each other. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. In the appended

5 claims, the terms “including” and “in which” are used as the plain-English equivalents of the respective terms “comprising” and “wherein.”